Using interactions between viral peptides and human proteins as a starting point, researchers from Enyo Pharma Inc., the University of Lyon and other institutions were able to bootstrap themselves to a mitochondria-targeting small molecule that showed activity in a mouse model of nonalcoholic steatohepatitis (NASH) with chronic kidney disease. Read More
Collagen prolyl 4-hydroxylase (P4H) is an α-ketoglutarate (α-KG)-dependent dioxygenase, and prolyl 4-hydroxylase subunit α1 (P4HA1) is the major isoform among the catalytic subunits of P4H. It has been previously demonstrated that P4HA1 promotes angiogenesis in tumors, and bioinformatics analysis has identified P4HA1 as a glycolysis-related gene in various cancers. Read More
Vesper Bio ApS has been awarded a grant worth $873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease. Read More
Reithera Srl, The Ragon Institute of Mass General, MIT and Harvard, and IAVI have established a collaboration to develop a novel HIV vaccine candidate based on gorilla adenoviral vector (GRAd), with funding by the Bill & Melinda Gates Foundation. Read More
Researchers from Universidade Federal de Minas Gerais have published details on the discovery of novel anti-SARS-CoV-2 compounds with robust antiviral activity. Read More
The Kv1.1 potassium channel regulates neuronal excitability both in the central and peripheral nervous systems and its dysfunction is associated with epilepsy, among others. Read More
Simultaneous inhibition of the phosphoinositide 3-kinase (PI3K) signaling pathway and histone deacetylase (HDAC) provides synergistic efficacy in the treatment of hematological malignancies. Read More
Strand Therapeutics Inc. has received IND clearance from the FDA to initiate a first-in-human phase I trial of STX-001 as a new approach for the treatment of solid tumors. Read More
Several highly pathogenic viruses, including SARS-CoV-2, share a conserved mechanism of infection via the fusion of the viral and host membranes employing a six-helix bundle (6-HB) heptad repeat. Read More
Medshine Discovery Inc. has synthesized amino-substituted heteroaryl derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer. Read More
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) ligase binding moiety covalently bonded to a histone deacetylase (HDAC) targeting moiety through a linker. Read More
NK Celltech Co. Ltd. has announced FDA clearance for a clinical trial of NK-010, a nongenetically modified allogeneic peripheral blood natural killer (NK) cell drug. Read More
The EMA has awarded orphan drug designation to GC Biopharma Corp.’s intracerebroventricular enzyme replacement therapy (ERT) candidate, GC-1130A, for mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A), developed in collaboration with Novel Pharma Inc. Read More
CDR-Life Inc. has announced FDA clearance of an IND application for CDR-404, its lead program in development as a precision immunotherapy for solid tumors. Read More
Bioversys AG has described 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4h)-one derivatives with the ability to interact with accessory gene regulator A (AgrA) and inhibit the expression of AgrA-regulated virulence factors reported to be useful for the treatment of bacterial infections and skin inflammation. Read More
